Medical Cannabis for Depression — Switzerland 2026
Cannabis is not a first-line antidepressant — but a documented off-label option in treatment-resistant depression. Much cheaper for CannabisClub members.
Depression affects ~7 % of the Swiss population, one third treatment-resistant. Cannabinoids act via CB1 on mood, sleep and anhedonia. CBD shows antidepressant effects without abuse potential; THC micro-doses (2.5–5 mg evenings) may help anhedonia and sleep. CannabisClub members: 50 CHF flat instead of 190.
What the studies show
Sales 2019 (RCT, n=28): CBD 300 mg reduced depressive symptoms vs placebo in 1 week.
Cuttler 2018 (observational, n=1,819): cannabis reduced symptoms in 89.3 % short-term.
When cannabis makes sense
After ≥2 failed antidepressant trials (SSRI, SNRI) or intolerable side effects.
With comorbid sleep disorder, pain or anxiety — depression benefits indirectly.
Preparations & dosing
CBD oil 25–50 mg twice daily as base — evidence-based, no sedation.
THC micro-dose 2.5 mg evenings for anhedonia/sleep, titrate slowly.
Save as a CannabisClub member
Psychiatric practices charge 190–250 CHF for first cannabis consult. Members: 50 CHF flat, prescription included. Registration free.
FAQ
Does cannabis replace my antidepressant?
No. Add-on in resistance or side effects. Discontinue only with treating physician.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
Rarely — depression is not a standard art. 71a indication. Usually out of pocket.
Cannabis for Depression — Prescription Switzerland 2026 (Members 50 CHF)